Merck Digital Sciences Studio

Dannce.ai specializes in developing markerless 3D motion capture technology, DANNCE, which employs deep learning to quantify behavior and detect neurological diseases. By analyzing fine 3D patient movement, Dannce.ai creates distinct 'behavioral fingerprints' that correspond to specific disease states and drug effects, accelerating drug development and enhancing diagnostic accessibility.

Pepper Bio is a trans-omics company dedicated to advancing drug discovery through the integration of various biological data types, including phosphoproteomics, proteomics, transcriptomics, and genomics. By focusing on neurodegenerative diseases, inflammatory conditions, and oncology, the company aims to develop treatments for previously untreatable diseases. Its innovative transomics platform offers comprehensive insights into biological functions, which can aid researchers and medical professionals in identifying and targeting therapeutic opportunities, ultimately enhancing the potential to cure complex diseases like cancer.

DeepSeq.AI, founded in 2019, specializes in protein engineering by leveraging artificial intelligence and machine learning to enhance drug discovery processes. The company has developed a next-generation sequencing platform that focuses on decoding the relationship between protein sequences and their functions. This innovative platform enables pharmaceutical companies to design novel protein drugs with increased speed and accuracy. DeepSeq.AI has collaborated with leading biopharmaceutical firms to conduct feasibility studies aimed at accelerating drug discovery efforts. Their successes in these collaborations were highlighted at the Protein Engineering Summit Boston in May 2023, where they presented alongside prominent industry players. By utilizing advanced screening strategies, DeepSeq.AI’s technology clusters and analyzes proteins based on their physical properties, predicts interactions, and creates synthetic sequences, thereby offering researchers a smarter and more efficient approach to drug development.

Perceiv AI is an innovative healthcare company focused on advancing precision medicine through the application of artificial intelligence. The company aims to enhance patient care by improving the efficiency and accuracy of subject targeting and prognosis using sophisticated machine learning algorithms. Perceiv AI addresses the complexities of clinical trials by helping pharmaceutical companies identify the most suitable populations for treatment, thereby increasing the likelihood of successful outcomes. Its AI-driven precision medicine platform integrates various types of longitudinal data—including imaging, genetic, phenotypic, and clinical variables—to create detailed profiles of individuals. This allows healthcare organizations and pharmaceutical firms to better target at-risk individuals, particularly in challenging areas like age-related diseases, including CNS/Alzheimer's disease and cardiovascular conditions.